DVA Medical Fee Schedule Tracker

Showing 5151–5200 of 5886 Pg 104/118

	Item No.	Description	Category	MBS Fee	DVA Fee
	73074	A test, including partial genotyping, for oncogenic human papillomavirus, for the investigation of a patient following a total hysterectomy.	Category 6 — Pathology	$36.80	$35.85 ▼
Item Number 73074 Fee Comparison MBS $36.80 → DVA $35.85 -$0.95 (-3%) Additional DVA Rates Pathology Fee $35.85 Full Description A test, including partial genotyping, for oncogenic human papillomavirus, for the investigation of a patient following a total hysterectomy. Sign in to watch this code → Get an email alert when this item changes
	73075	A test, including partial genotyping, for oncogenic human papillomavirus, if: (a) the test is a repeat of a test to which item 73070, 73071, 73072, 73074 or this item applies; and (b) the specimen collected for the previous test is unsatisfactory	Category 6 — Pathology	$36.80	$35.85 ▼
Item Number 73075 Fee Comparison MBS $36.80 → DVA $35.85 -$0.95 (-3%) Additional DVA Rates Pathology Fee $35.85 Full Description A test, including partial genotyping, for oncogenic human papillomavirus, if: (a) the test is a repeat of a test to which item 73070, 73071, 73072, 73074 or this item applies; and (b) the specimen collected for the previous test is unsatisfactory Sign in to watch this code → Get an email alert when this item changes
	73076	Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if: (a) the cytology is associated with the detection of oncogenic human papillomavirus infection by: (i) a test to which item 73070, 73071, 73074 or 73075 applies; or (ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or (b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or (c) the cytology is associated with a test to which item 73074 applies; or (d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or (e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma	Category 6 — Pathology	$48.30	$47.10 ▼
Item Number 73076 Fee Comparison MBS $48.30 → DVA $47.10 -$1.20 (-2%) Additional DVA Rates Pathology Fee $47.10 Full Description Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if: (a) the cytology is associated with the detection of oncogenic human papillomavirus infection by: (i) a test to which item 73070, 73071, 73074 or 73075 applies; or (ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or (b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or (c) the cytology is associated with a test to which item 73074 applies; or (d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or (e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma Sign in to watch this code → Get an email alert when this item changes
	73287	The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests	Category 6 — Pathology	$394.55	$394.55
Item Number 73287 Fee Comparison MBS $394.55 → DVA $394.55 Additional DVA Rates Pathology Fee $394.55 Full Description The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73289	The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests	Category 6 — Pathology	$358.95	$358.95
Item Number 73289 Fee Comparison MBS $358.95 → DVA $358.95 Additional DVA Rates Pathology Fee $358.95 Full Description The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73290	The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoringof haematological malignancy (including a service in items 73287 or 73289, if performed). - 1 or more tests.	Category 6 — Pathology	$394.55	$394.55
Item Number 73290 Fee Comparison MBS $394.55 → DVA $394.55 Additional DVA Rates Pathology Fee $394.55 Full Description The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoringof haematological malignancy (including a service in items 73287 or 73289, if performed). - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73291	Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or b) studies of a relative for an abnormality previously identified in such an affected person. - 1 or more tests.	Category 6 — Pathology	$230.95	$230.95
Item Number 73291 Fee Comparison MBS $230.95 → DVA $230.95 Additional DVA Rates Pathology Fee $230.95 Full Description Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or b) studies of a relative for an abnormality previously identified in such an affected person. - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73292	Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in items 73287, 73289 or 73291, if performed) - 1 or more tests.	Category 6 — Pathology	$589.90	$589.90
Item Number 73292 Fee Comparison MBS $589.90 → DVA $589.90 Additional DVA Rates Pathology Fee $589.90 Full Description Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in items 73287, 73289 or 73291, if performed) - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73293	Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination. - 1 or more tests.	Category 6 — Pathology	$230.95	$230.95
Item Number 73293 Fee Comparison MBS $230.95 → DVA $230.95 Additional DVA Rates Pathology Fee $230.95 Full Description Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination. - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73294	Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as: a) diagnostic studies of an affected person; or b) studies of a relative for an abnormality previously identified in an affected person - 1 or more tests.	Category 6 — Pathology	$230.95	$230.95
Item Number 73294 Fee Comparison MBS $230.95 → DVA $230.95 Additional DVA Rates Pathology Fee $230.95 Full Description Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as: a) diagnostic studies of an affected person; or b) studies of a relative for an abnormality previously identified in an affected person - 1 or more tests. Sign in to watch this code → Get an email alert when this item changes
	73295	Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with: (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or (b) breast cancer. Applicable once per lifetime	Category 6 — Pathology	$1200.00	$1200.00
Item Number 73295 Fee Comparison MBS $1200.00 → DVA $1200.00 Additional DVA Rates Pathology Fee $1200.00 Full Description Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with: (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or (b) breast cancer. Applicable once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73296	Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which must include at least: (i) BRCA1 and BRCA 2 genes; and (ii) one or more other relevant genes; and (b) in a patient: (i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and (ii) for whom clinical and family history criteria place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene associated with breast, ovarian, fallopian tube or primary peritoneal cancer Once per cancer diagnosis	Category 6 — Pathology	$1200.00	$1200.00
Item Number 73296 Fee Comparison MBS $1200.00 → DVA $1200.00 Additional DVA Rates Pathology Fee $1200.00 Full Description Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which must include at least: (i) BRCA1 and BRCA 2 genes; and (ii) one or more other relevant genes; and (b) in a patient: (i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and (ii) for whom clinical and family history criteria place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene associated with breast, ovarian, fallopian tube or primary peritoneal cancer Once per cancer diagnosis Sign in to watch this code → Get an email alert when this item changes
	73297	Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which may include the following genes: (i) BRCA1 or BRCA2; (ii) one or more other relevant genes; and (b) in a patient: (i) who has a biological relative who has had a pathogenic or likely pathogenic gene variant identified in one or more of the genes mentioned in paragraph (a); and (ii) who has not previously received a service to which item 73295, 73296 or 73302 applies Once per variant	Category 6 — Pathology	$400.00	$400.00
Item Number 73297 Fee Comparison MBS $400.00 → DVA $400.00 Additional DVA Rates Pathology Fee $400.00 Full Description Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which may include the following genes: (i) BRCA1 or BRCA2; (ii) one or more other relevant genes; and (b) in a patient: (i) who has a biological relative who has had a pathogenic or likely pathogenic gene variant identified in one or more of the genes mentioned in paragraph (a); and (ii) who has not previously received a service to which item 73295, 73296 or 73302 applies Once per variant Sign in to watch this code → Get an email alert when this item changes
	73298	Characterisation of germline gene variants in the following genes: (a) COL4A3; and (b) COL4A4; and (c) COL4A5; in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome.	Category 6 — Pathology	$1200.00	$1200.00
Item Number 73298 Fee Comparison MBS $1200.00 → DVA $1200.00 Additional DVA Rates Pathology Fee $1200.00 Full Description Characterisation of germline gene variants in the following genes: (a) COL4A3; and (b) COL4A4; and (c) COL4A5; in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome. Sign in to watch this code → Get an email alert when this item changes
	73299	Characterisation of germline gene variants: (a) in the following genes: (i) COL4A3; and (ii) COL4A4; and (iii) COL4A5; (b) in a patient who: (i) is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and (ii) has not previously received a service which item 73298 applies; requested by a specialist or consultant physician.	Category 6 — Pathology	$400.00	$400.00
Item Number 73299 Fee Comparison MBS $400.00 → DVA $400.00 Additional DVA Rates Pathology Fee $400.00 Full Description Characterisation of germline gene variants: (a) in the following genes: (i) COL4A3; and (ii) COL4A4; and (iii) COL4A5; (b) in a patient who: (i) is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and (ii) has not previously received a service which item 73298 applies; requested by a specialist or consultant physician. Sign in to watch this code → Get an email alert when this item changes
	73300	Detection of mutation of the FMR1 gene where: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or (b) the patient has a relative with a FMR1 mutation 1 or more tests	Category 6 — Pathology	$101.30	$101.30
Item Number 73300 Fee Comparison MBS $101.30 → DVA $101.30 Additional DVA Rates Pathology Fee $101.30 Full Description Detection of mutation of the FMR1 gene where: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or (b) the patient has a relative with a FMR1 mutation 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73301	A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) Applicable once per primary tumour diagnosis	Category 6 — Pathology	$1200.00	$1200.00
Item Number 73301 Fee Comparison MBS $1200.00 → DVA $1200.00 Additional DVA Rates Pathology Fee $1200.00 Full Description A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73302	Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician. Applicable once per primary tumour diagnosis	Category 6 — Pathology	$400.00	$400.00
Item Number 73302 Fee Comparison MBS $400.00 → DVA $400.00 Additional DVA Rates Pathology Fee $400.00 Full Description Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician. Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73303	A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per primary tumour diagnosis	Category 6 — Pathology	$1000.00	$1000.00
Item Number 73303 Fee Comparison MBS $1000.00 → DVA $1000.00 Additional DVA Rates Pathology Fee $1000.00 Full Description A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73304	Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per lifetime	Category 6 — Pathology	$1000.00	$1000.00
Item Number 73304 Fee Comparison MBS $1000.00 → DVA $1000.00 Additional DVA Rates Pathology Fee $1000.00 Full Description Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73305	Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive	Category 6 — Pathology	$202.65	$202.65
Item Number 73305 Fee Comparison MBS $202.65 → DVA $202.65 Additional DVA Rates Pathology Fee $202.65 Full Description Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive Sign in to watch this code → Get an email alert when this item changes
	73306	Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if: (a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and (b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and (c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and (d) the sample has no evidence of distal metastasis; and (e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics: (i) histopathological grade 2 or 3; (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and (f) the service is not administered for the purpose of altering treatment decisions Applicable once per new primary breast cancer diagnosis for any particular patient	Category 6 — Pathology	$1200.00	$1200.00
Item Number 73306 Fee Comparison MBS $1200.00 → DVA $1200.00 Additional DVA Rates Pathology Fee $1200.00 Full Description Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if: (a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and (b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and (c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and (d) the sample has no evidence of distal metastasis; and (e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics: (i) histopathological grade 2 or 3; (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and (f) the service is not administered for the purpose of altering treatment decisions Applicable once per new primary breast cancer diagnosis for any particular patient Sign in to watch this code → Get an email alert when this item changes
	73307	A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is: (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and (b) including a service described in item 73301 Applicable once per primary tumour diagnosis	Category 6 — Pathology	$3000.00	$3000.00
Item Number 73307 Fee Comparison MBS $3000.00 → DVA $3000.00 Additional DVA Rates Pathology Fee $3000.00 Full Description A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is: (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and (b) including a service described in item 73301 Applicable once per primary tumour diagnosis Sign in to watch this code → Get an email alert when this item changes
	73308	Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests	Category 6 — Pathology	$36.45	$36.45
Item Number 73308 Fee Comparison MBS $36.45 → DVA $36.45 Additional DVA Rates Pathology Fee $36.45 Full Description Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73309	A test described in item 73308, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)	Category 6 — Pathology	$36.45	$36.45
Item Number 73309 Fee Comparison MBS $36.45 → DVA $36.45 Additional DVA Rates Pathology Fee $36.45 Full Description A test described in item 73308, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Sign in to watch this code → Get an email alert when this item changes
	73310	Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist	Category 6 — Pathology	$1550.00	$1550.00
Item Number 73310 Fee Comparison MBS $1550.00 → DVA $1550.00 Additional DVA Rates Pathology Fee $1550.00 Full Description Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist Sign in to watch this code → Get an email alert when this item changes
	73311	Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests	Category 6 — Pathology	$36.45	$36.45
Item Number 73311 Fee Comparison MBS $36.45 → DVA $36.45 Additional DVA Rates Pathology Fee $36.45 Full Description Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73312	A test described in item 73311, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)	Category 6 — Pathology	$36.45	$36.45
Item Number 73312 Fee Comparison MBS $36.45 → DVA $36.45 Additional DVA Rates Pathology Fee $36.45 Full Description A test described in item 73311, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Sign in to watch this code → Get an email alert when this item changes
	73313	Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist Applicable once per patient per episode of disease or per relapse	Category 6 — Pathology	$3000.00	$3000.00
Item Number 73313 Fee Comparison MBS $3000.00 → DVA $3000.00 Additional DVA Rates Pathology Fee $3000.00 Full Description Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist Applicable once per patient per episode of disease or per relapse Sign in to watch this code → Get an email alert when this item changes
	73314	Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia;	Category 6 — Pathology	$230.95	$230.95
Item Number 73314 Fee Comparison MBS $230.95 → DVA $230.95 Additional DVA Rates Pathology Fee $230.95 Full Description Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia; Sign in to watch this code → Get an email alert when this item changes
	73315	A test described in item 73314, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)	Category 6 — Pathology	$230.95	$230.95
Item Number 73315 Fee Comparison MBS $230.95 → DVA $230.95 Additional DVA Rates Pathology Fee $230.95 Full Description A test described in item 73314, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18) Sign in to watch this code → Get an email alert when this item changes
	73316	Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies	Category 6 — Pathology	$780.00	$780.00
Item Number 73316 Fee Comparison MBS $780.00 → DVA $780.00 Additional DVA Rates Pathology Fee $780.00 Full Description Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies Sign in to watch this code → Get an email alert when this item changes
	73317	Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20)	Category 6 — Pathology	$36.45	$36.45
Item Number 73317 Fee Comparison MBS $36.45 → DVA $36.45 Additional DVA Rates Pathology Fee $36.45 Full Description Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20) Sign in to watch this code → Get an email alert when this item changes
	73318	A test described in item 73317, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18 and 20)	Category 6 — Pathology	$36.45	$36.45
Item Number 73318 Fee Comparison MBS $36.45 → DVA $36.45 Additional DVA Rates Pathology Fee $36.45 Full Description A test described in item 73317, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18 and 20) Sign in to watch this code → Get an email alert when this item changes
	73319	Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme. Applicable only once per lifetime	Category 6 — Pathology	$340.00	$340.00
Item Number 73319 Fee Comparison MBS $340.00 → DVA $340.00 Additional DVA Rates Pathology Fee $340.00 Full Description Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme. Applicable only once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73320	Detection of HLA-B27 by nucleic acid amplification includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service. (Item is subject to rule 27)	Category 6 — Pathology	$40.55	$40.55
Item Number 73320 Fee Comparison MBS $40.55 → DVA $40.55 Additional DVA Rates Pathology Fee $40.55 Full Description Detection of HLA-B27 by nucleic acid amplification includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service. (Item is subject to rule 27) Sign in to watch this code → Get an email alert when this item changes
	73321	A test described in item 73320, if rendered by a receiving APP - 1 or more tests. (Item is subject to rule 18 and 27)	Category 6 — Pathology	$40.55	$40.55
Item Number 73321 Fee Comparison MBS $40.55 → DVA $40.55 Additional DVA Rates Pathology Fee $40.55 Full Description A test described in item 73320, if rendered by a receiving APP - 1 or more tests. (Item is subject to rule 18 and 27) Sign in to watch this code → Get an email alert when this item changes
	73322	Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime	Category 6 — Pathology	$186.75	$182.00 ▼
Item Number 73322 Fee Comparison MBS $186.75 → DVA $182.00 -$4.75 (-3%) Additional DVA Rates Pathology Fee $182.00 Full Description Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime Sign in to watch this code → Get an email alert when this item changes
	73323	Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed.	Category 6 — Pathology	$40.55	$40.55
Item Number 73323 Fee Comparison MBS $40.55 → DVA $40.55 Additional DVA Rates Pathology Fee $40.55 Full Description Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed. Sign in to watch this code → Get an email alert when this item changes
	73324	A test described in item 73323 if rendered by a receiving APP 1 or more tests (Item is subject to Rule 18)	Category 6 — Pathology	$40.95	$40.95
Item Number 73324 Fee Comparison MBS $40.95 → DVA $40.95 Additional DVA Rates Pathology Fee $40.95 Full Description A test described in item 73323 if rendered by a receiving APP 1 or more tests (Item is subject to Rule 18) Sign in to watch this code → Get an email alert when this item changes
	73325	Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm	Category 6 — Pathology	$90.00	$90.00
Item Number 73325 Fee Comparison MBS $90.00 → DVA $90.00 Additional DVA Rates Pathology Fee $90.00 Full Description Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm Sign in to watch this code → Get an email alert when this item changes
	73326	Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of: a) mast cell disease; or b) idiopathic hypereosinophilic syndrome; or c) chronic eosinophilic leukaemia;. 1 or more tests	Category 6 — Pathology	$230.95	$230.95
Item Number 73326 Fee Comparison MBS $230.95 → DVA $230.95 Additional DVA Rates Pathology Fee $230.95 Full Description Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of: a) mast cell disease; or b) idiopathic hypereosinophilic syndrome; or c) chronic eosinophilic leukaemia;. 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73327	Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075. 1 or more tests	Category 6 — Pathology	$51.95	$51.95
Item Number 73327 Fee Comparison MBS $51.95 → DVA $51.95 Additional DVA Rates Pathology Fee $51.95 Full Description Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075. 1 or more tests Sign in to watch this code → Get an email alert when this item changes
	73332	An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled.	Category 6 — Pathology	$315.40	$315.40
Item Number 73332 Fee Comparison MBS $315.40 → DVA $315.40 Additional DVA Rates Pathology Fee $315.40 Full Description An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled. Sign in to watch this code → Get an email alert when this item changes
	73333	Detection of germline mutations of the von Hippel‑Lindau (VHL) gene: (a) in a patient who has a clinical diagnosis of VHL syndrome and: (i) a family history of VHL syndrome and one of the following: (A) haemangioblastoma (retinal or central nervous system); (B) phaeochromocytoma; (C) renal cell carcinoma; or (ii) 2 or more haemangioblastomas; or (iii) one haemangioblastoma and a tumour or a cyst of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; or (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome: (i) haemangiblastomas of the brain, spinal cord, or retina; (ii) phaeochromocytoma; (iii) functional extra‑adrenal paraganglioma	Category 6 — Pathology	$600.00	$600.00
Item Number 73333 Fee Comparison MBS $600.00 → DVA $600.00 Additional DVA Rates Pathology Fee $600.00 Full Description Detection of germline mutations of the von Hippel‑Lindau (VHL) gene: (a) in a patient who has a clinical diagnosis of VHL syndrome and: (i) a family history of VHL syndrome and one of the following: (A) haemangioblastoma (retinal or central nervous system); (B) phaeochromocytoma; (C) renal cell carcinoma; or (ii) 2 or more haemangioblastomas; or (iii) one haemangioblastoma and a tumour or a cyst of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; or (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome: (i) haemangiblastomas of the brain, spinal cord, or retina; (ii) phaeochromocytoma; (iii) functional extra‑adrenal paraganglioma Sign in to watch this code → Get an email alert when this item changes
	73334	Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene	Category 6 — Pathology	$340.00	$340.00
Item Number 73334 Fee Comparison MBS $340.00 → DVA $340.00 Additional DVA Rates Pathology Fee $340.00 Full Description Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene Sign in to watch this code → Get an email alert when this item changes
	73335	Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with: (a) 2 or more tumours comprising: (i) 2 or more haemangioblastomas, or (ii) one haemangioblastoma and a tumour of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; and (b) no germline mutations of the VHL gene identified by genetic testing	Category 6 — Pathology	$470.00	$470.00
Item Number 73335 Fee Comparison MBS $470.00 → DVA $470.00 Additional DVA Rates Pathology Fee $470.00 Full Description Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with: (a) 2 or more tumours comprising: (i) 2 or more haemangioblastomas, or (ii) one haemangioblastoma and a tumour of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; and (b) no germline mutations of the VHL gene identified by genetic testing Sign in to watch this code → Get an email alert when this item changes
	73336	A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.	Category 6 — Pathology	$230.95	$230.95
Item Number 73336 Fee Comparison MBS $230.95 → DVA $230.95 Additional DVA Rates Pathology Fee $230.95 Full Description A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. Sign in to watch this code → Get an email alert when this item changes
	73337	A test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for epidermal growth factor receptor (EGFR) status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies	Category 6 — Pathology	$397.35	$397.35
Item Number 73337 Fee Comparison MBS $397.35 → DVA $397.35 Additional DVA Rates Pathology Fee $397.35 Full Description A test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for epidermal growth factor receptor (EGFR) status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies Sign in to watch this code → Get an email alert when this item changes
	73338	A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if: (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if: the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or a clinically-relevant RAS variant is detected; and, in cases where no RAS variant is detected (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.	Category 6 — Pathology	$362.60	$362.60
Item Number 73338 Fee Comparison MBS $362.60 → DVA $362.60 Additional DVA Rates Pathology Fee $362.60 Full Description A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if: (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if: the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or a clinically-relevant RAS variant is detected; and, in cases where no RAS variant is detected (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled. Sign in to watch this code → Get an email alert when this item changes

MBS Fee

$36.80

DVA Fee

$35.85

Category

Category 6 — Pathology

Description

A test, including partial genotyping, for oncogenic human papillomavirus, for the investigation of a patient following a total hysterectomy.

MBS Fee

$36.80

DVA Fee

$35.85

Category

Category 6 — Pathology

Description

A test, including partial genotyping, for oncogenic human papillomavirus, if: (a) the test is a repeat of a test to which item 73070, 73071, 73072, 73074 or this item applies; and (b) the specimen collected for the previous test is unsatisfactory

MBS Fee

$48.30

DVA Fee

$47.10

Category

Category 6 — Pathology

Description

Cytology of a liquid‑based cervical or vaginal vault specimen, where the stained cells are examined microscopically or by automated image analysis by or on behalf of a pathologist, if: (a) the cytology is associated with the detection of oncogenic human papillomavirus infection by: (i) a test to which item 73070, 73071, 73074 or 73075 applies; or (ii) a test to which item 73072 applies for a patient mentioned in paragraph (a) or (b) of that item; or (b) the cytology is associated with a test to which item 73072 applies for a patient mentioned in paragraph (c), (d), (e) or (f) of that item; or (c) the cytology is associated with a test to which item 73074 applies; or (d) the test is a repeat of a test to which this item applies, if the specimen collected for the previous test is unsatisfactory; or (e) the cytology is for the follow‑up management of a patient treated for endometrial adenocarcinoma

MBS Fee

$394.55

DVA Fee

$394.55

Category

Category 6 — Pathology

Description

The study of the whole of every chromosome by cytogenetic or other techniques, performed on 1 or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed) - 1 or more tests

MBS Fee

$358.95

DVA Fee

$358.95

Category

Category 6 — Pathology

Description

The study of the whole of every chromosome by cytogenetic or other techniques, performed on blood (including a service mentioned in item 73293, if performed) - 1 or more tests

MBS Fee

$394.55

DVA Fee

$394.55

Category

Category 6 — Pathology

Description

The study of the whole of each chromosome by cytogenetic or other techniques, performed on blood or bone marrow, in the diagnosis and monitoringof haematological malignancy (including a service in items 73287 or 73289, if performed). - 1 or more tests.

MBS Fee

$230.95

DVA Fee

$230.95

Category

Category 6 — Pathology

Description

Analysis of one or more chromosome regions for specific constitutional genetic abnormalities of blood or fresh tissue in a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities, in whom cytogenetic studies (item 73287 or 73289) are either normal or have not been performed; or b) studies of a relative for an abnormality previously identified in such an affected person. - 1 or more tests.

MBS Fee

$589.90

DVA Fee

$589.90

Category

Category 6 — Pathology

Description

Analysis of chromosomes by genome-wide micro-array including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least two congenital abnormalities (including a service in items 73287, 73289 or 73291, if performed) - 1 or more tests.

MBS Fee

$230.95

DVA Fee

$230.95

Category

Category 6 — Pathology

Description

Analysis of one or more regions on all chromosomes for specific constitutional genetic abnormalities of fresh tissue in diagnostic studies of the products of conception, including exclusion of maternal cell contamination. - 1 or more tests.

MBS Fee

$230.95

DVA Fee

$230.95

Category

Category 6 — Pathology

Description

Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, either as: a) diagnostic studies of an affected person; or b) studies of a relative for an abnormality previously identified in an affected person - 1 or more tests.

MBS Fee

$1200.00

DVA Fee

$1200.00

Category

Category 6 — Pathology

Description

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with: (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or (b) breast cancer. Applicable once per lifetime

MBS Fee

$1200.00

DVA Fee

$1200.00

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which must include at least: (i) BRCA1 and BRCA 2 genes; and (ii) one or more other relevant genes; and (b) in a patient: (i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and (ii) for whom clinical and family history criteria place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene associated with breast, ovarian, fallopian tube or primary peritoneal cancer Once per cancer diagnosis

MBS Fee

$400.00

DVA Fee

$400.00

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants, including copy number variation where appropriate, requested by a specialist or consultant physician: (a) in genes associated with breast, ovarian, fallopian tube or primary peritoneal cancer, which may include the following genes: (i) BRCA1 or BRCA2; (ii) one or more other relevant genes; and (b) in a patient: (i) who has a biological relative who has had a pathogenic or likely pathogenic gene variant identified in one or more of the genes mentioned in paragraph (a); and (ii) who has not previously received a service to which item 73295, 73296 or 73302 applies Once per variant

MBS Fee

$1200.00

DVA Fee

$1200.00

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants in the following genes: (a) COL4A3; and (b) COL4A4; and (c) COL4A5; in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome.

MBS Fee

$400.00

DVA Fee

$400.00

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants: (a) in the following genes: (i) COL4A3; and (ii) COL4A4; and (iii) COL4A5; (b) in a patient who: (i) is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and (ii) has not previously received a service which item 73298 applies; requested by a specialist or consultant physician.

MBS Fee

$101.30

DVA Fee

$101.30

Category

Category 6 — Pathology

Description

Detection of mutation of the FMR1 gene where: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or (b) the patient has a relative with a FMR1 mutation 1 or more tests

MBS Fee

$1200.00

DVA Fee

$1200.00

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS) Applicable once per primary tumour diagnosis

MBS Fee

$400.00

DVA Fee

$400.00

Category

Category 6 — Pathology

Description

Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician. Applicable once per primary tumour diagnosis

MBS Fee

$1000.00

DVA Fee

$1000.00

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per primary tumour diagnosis

MBS Fee

$1000.00

DVA Fee

$1000.00

Category

Category 6 — Pathology

Description

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; Applicable once per lifetime

MBS Fee

$202.65

DVA Fee

$202.65

Category

Category 6 — Pathology

Description

Detection of mutation of the FMR1 gene by Southern Blot analysis where the results in item 73300 are inconclusive

MBS Fee

$1200.00

DVA Fee

$1200.00

Category

Category 6 — Pathology

Description

Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if: (a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and (b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and (c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and (d) the sample has no evidence of distal metastasis; and (e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics: (i) histopathological grade 2 or 3; (ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and (f) the service is not administered for the purpose of altering treatment decisions Applicable once per new primary breast cancer diagnosis for any particular patient

MBS Fee

$3000.00

DVA Fee

$3000.00

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is: (a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and (b) including a service described in item 73301 Applicable once per primary tumour diagnosis

MBS Fee

$36.45

DVA Fee

$36.45

Category

Category 6 — Pathology

Description

Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of the other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism - 1 or more tests

MBS Fee

$36.45

DVA Fee

$36.45

Category

Category 6 — Pathology

Description

A test described in item 73308, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)

MBS Fee

$1550.00

DVA Fee

$1550.00

Category

Category 6 — Pathology

Description

Measurable residual disease (MRD) testing by next-generation sequencing, performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia, for the purpose of determining baseline MRD, or facilitating the determination of MRD following combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist

MBS Fee

$36.45

DVA Fee

$36.45

Category

Category 6 — Pathology

Description

Characterisation of the genotype of a person who is a first degree relative of a person who has proven to have 1 or more abnormal genotypes under item 73308 - 1 or more tests

MBS Fee

$36.45

DVA Fee

$36.45

Category

Category 6 — Pathology

Description

A test described in item 73311, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)

MBS Fee

$3000.00

DVA Fee

$3000.00

Category

Category 6 — Pathology

Description

Development of a quantitative patient‑specific molecular assay for measurable residual disease (MRD) testing performed on bone marrow (or a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, including the first service described in item 73316 performed on that bone marrow or peripheral blood sample, requested by a specialist or consultant physician practising as a haematologist or oncologist Applicable once per patient per episode of disease or per relapse

MBS Fee

$230.95

DVA Fee

$230.95

Category

Category 6 — Pathology

Description

Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia;

MBS Fee

$230.95

DVA Fee

$230.95

Category

Category 6 — Pathology

Description

A test described in item 73314, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18)

MBS Fee

$780.00

DVA Fee

$780.00

Category

Category 6 — Pathology

Description

Measurable residual disease (MRD) testing by a quantitative patient-specific molecular assay performed on bone marrow (or, in a patient with T-cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies

MBS Fee

$36.45

DVA Fee

$36.45

Category

Category 6 — Pathology

Description

Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20)

MBS Fee

$36.45

DVA Fee

$36.45

Category

Category 6 — Pathology

Description

A test described in item 73317, if rendered by a receiving APP - 1 or more tests (Item is subject to rule 18 and 20)

MBS Fee

$340.00

DVA Fee

$340.00

Category

Category 6 — Pathology

Description

Detection in tumour tissue of isocitrate dehydrogenase 1 (IDH1) variant status, in a patient with histologically confirmed cholangiocarcinoma, to determine eligibility for a relevant treatment listed under the Pharmaceutical Benefits Scheme. Applicable only once per lifetime

MBS Fee

$40.55

DVA Fee

$40.55

Category

Category 6 — Pathology

Description

Detection of HLA-B27 by nucleic acid amplification includes a service described in 71147 unless the service in item 73320 is rendered as a pathologist determinable service. (Item is subject to rule 27)

MBS Fee

$40.55

DVA Fee

$40.55

Category

Category 6 — Pathology

Description

A test described in item 73320, if rendered by a receiving APP - 1 or more tests. (Item is subject to rule 18 and 27)

MBS Fee

$186.75

DVA Fee

$182.00

Category

Category 6 — Pathology

Description

Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if: (a) the service is requested by a specialist or consultant physician; and (b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and (c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity Applicable once per lifetime

MBS Fee

$40.55

DVA Fee

$40.55

Category

Category 6 — Pathology

Description

Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed.

MBS Fee

$40.95

DVA Fee

$40.95

Category

Category 6 — Pathology

Description

A test described in item 73323 if rendered by a receiving APP 1 or more tests (Item is subject to Rule 18)

MBS Fee

$90.00

DVA Fee

$90.00

Category

Category 6 — Pathology

Description

Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm

MBS Fee

$230.95

DVA Fee

$230.95

Category

Category 6 — Pathology

Description

Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of: a) mast cell disease; or b) idiopathic hypereosinophilic syndrome; or c) chronic eosinophilic leukaemia;. 1 or more tests

MBS Fee

$51.95

DVA Fee

$51.95

Category

Category 6 — Pathology

Description

Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075. 1 or more tests

MBS Fee

$315.40

DVA Fee

$315.40

Category

Category 6 — Pathology

Description

An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled.

MBS Fee

$600.00

DVA Fee

$600.00

Category

Category 6 — Pathology

Description

Detection of germline mutations of the von Hippel‑Lindau (VHL) gene: (a) in a patient who has a clinical diagnosis of VHL syndrome and: (i) a family history of VHL syndrome and one of the following: (A) haemangioblastoma (retinal or central nervous system); (B) phaeochromocytoma; (C) renal cell carcinoma; or (ii) 2 or more haemangioblastomas; or (iii) one haemangioblastoma and a tumour or a cyst of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; or (E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or (b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome: (i) haemangiblastomas of the brain, spinal cord, or retina; (ii) phaeochromocytoma; (iii) functional extra‑adrenal paraganglioma

MBS Fee

$340.00

DVA Fee

$340.00

Category

Category 6 — Pathology

Description

Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene

MBS Fee

$470.00

DVA Fee

$470.00

Category

Category 6 — Pathology

Description

Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with: (a) 2 or more tumours comprising: (i) 2 or more haemangioblastomas, or (ii) one haemangioblastoma and a tumour of: (A) the adrenal gland; or (B) the kidney; or (C) the pancreas; or (D) the epididymis; and (b) no germline mutations of the VHL gene identified by genetic testing

MBS Fee

$230.95

DVA Fee

$230.95

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.

MBS Fee

$397.35

DVA Fee

$397.35

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer, requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) for epidermal growth factor receptor (EGFR) status to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (b) not associated with a service to which item 73437 or 73438 applies

MBS Fee

$362.60

DVA Fee

$362.60

Category

Category 6 — Pathology

Description

A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if: (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if: the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or a clinically-relevant RAS variant is detected; and, in cases where no RAS variant is detected (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.

← Prev 102 103 104 105 106 Next →

50 items per page · tap/click any row to expand